Navigation Links
New Hope for Tough-to-Treat Cancers
Date:5/31/2008

Gemzar, everolimus almost doubled survival time with pancreatic, kidney cancers, respectively

SATURDAY, May 31 (HealthDay News) -- Patients diagnosed with pancreatic cancer -- which historically carries a grim prognosis -- nearly doubled their overall survival when the cancer drug Gemzar was used after surgery, new research shows.

Unfortunately, only about 15 percent of pancreatic cancer patients are even candidates for surgery.

"Pancreatic cancer is probably the deadliest cancer that we face," said Dr. Richard Schilsky, president-elect of the American Society of Clinical Oncology (ASCO) and a professor of medicine at the University of Chicago. "It's frequently not even diagnosed until it's very far advanced, when treatments are not very effective."

Schilsky spoke at a teleconference earlier this month; the results of the new trial, a follow-up from data first presented in 2005, were released Saturday at ASCO's annual meeting in Chicago.

Gemzar (gemcitabine) is the standard treatment for pancreatic cancer that can't be removed surgically.

At three years, 23.5 percent of participants taking Gemzar had survived without a recurrence, versus 7.5 percent in the placebo group; that number dropped to 16.5 percent at five years, versus 5.5 percent in the control arm.

Overall, 36.5 percent of Gemzar patients were still alive at the five-year mark (vs. 19.5 percent in the placebo group) and 21 percent were still alive after five years (vs. 9 percent in placebo).

"Treatment with gemcitabine as compared to observational in patients with resected [surgically removed] pancreatic cancer resulted in improvements in disease-free survival and overall survival," said study co-author Dr. Helmut Oettle, of Charite University Medical School in Berlin. "Adjuvant treatment [with Gemzar] doubled long-term survival rate after five years compared with the observation group. Gemcitabine should be the standard of care for adjuvant treatment of pancreatic patients."

"This represents a very substantial improvement in outcome for these individuals, and I think we can look forward to seeing widespread adoption of gemcitabine for patients with pancreatic cancer that can be surgically removed," Schilsky said.

Researchers at the ASCO meeting also reported progress with another tough-to-treat cancer, advanced kidney cancer.

While there have been significant advances in recent years with drugs such as Sutent (sunitinib), that success has brought a new challenge: How to treat patients who don't respond to the latest generation of new therapies.

Enter everolimus, a drug which interferes with blood supply to the tumor and which is one of the first in a relatively new class of compounds. Patients randomized to receive everolimus plus best existing therapy had a 70 percent reduction in the risk of recurrence or death, compared to patients who received best existing therapy alone. For patients on everolimus, it took about four months for the cancer to return, versus about two months in the placebo group.

"While that may not sound like an enormous leap forward, it's actually a very important observation for several reasons," Schilsky explained. "This drug is targeting a different molecular pathway compared to anti-angiogenesis drugs [those that block blood supply to the tumor], so it's working in a completely different way. Secondly, when we make these observations, not only do patients benefit from a delay in progression of their cancer, but this kind of observation always gives us a new lead and an interest in moving these drugs up earlier into cancer treatment."

"A setting of unmet clinical need that has now been filled," added study author Dr. Robert Motzer, an attending physician at Memorial Sloan-Kettering Cancer Center in New York City. "Everolimus should be the standard of care in this setting, pending approval by regulatory authorities."

More information

The National Cancer Institute has more on pancreatic cancer.



SOURCES: May 31, 2008, news conference with Helmut Oettle, M.D., Ph.D., Charite School of Medicine, Berlin, and Robert Motzer, M.D., attending physician, Memorial Sloan-Kettering Cancer Center, New York City; May 15, 2008, teleconference with Richard Schilsky, M.D., president-elect, American Society of Clinical Oncology, and professor, medicine, University of Chicago; May 31, 2008, presentations, American Society of Clinical Oncology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New Drug Promising Against Tough-to-Treat Kidney Cancer
2. NEW DATA FOR PAZOPANIB - GSKS LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS
3. Laser Therapy a New Option for Vocal-Cord Cancers
4. Data re-analysis shows drug finasteride reduces risk for most prostate cancers
5. Radiation for Prostate Cancer Raises Risk of Other Cancers
6. Kidney Cancers More Likely to Be Diagnosed Early
7. Majority of kidney cancers diagnosed at earliest stage
8. High-Tech Imaging No Better for Diagnosing Head/Neck Cancers
9. Coupled With Mammography, Ultrasound Finds More Breast Cancers
10. New Treatment Offers Hope for Beating Aggressive Cancers
11. Potential viral therapy weapon for difficult cancers is safe and effective in study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... PA (PRWEB) , ... March 28, 2017 , ... ... for and by physicians, announced today the launch of a free, public-facing tool ... Via Cost Analyzer (VCA) was developed to provide comparative information to patients, providers, ...
(Date:3/28/2017)... ... , ... WHO: , Dr. Paul Thomas; Dr. Brian Hooker; Dr. Judy Mikovits; ... scientists will speak to the press on behalf of over 200 doctors, scientists, and ... safety commission. , WHERE: , Zenger Room, National Press Club, 529 14th Street ...
(Date:3/28/2017)... Switzerland (PRWEB) , ... March 28, 2017 , ... ... for laboratory instruments are critical to ensuring high-quality results and maintaining GMP and ... Qualification of Laboratory Instruments in accordance with GMP requirements " these requirements are ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , a provider ... and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and ... biometric face recognition to enable users to check in and out from anywhere ...
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 ... expected to reach a value of USD 4.5 billion ... View Research, Inc. Proper closure of injured tissues post ... and function. Postoperative leakages occur in 3% to 15% ... They are responsible for one third of postoperative deaths ...
(Date:3/27/2017)... , March 27, 2017 ... to better understand Bayer and its partnering interests and activities ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ... company data. The report will be delivered in ...
(Date:3/27/2017)... 2017  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or ... shares of common stock in an underwritten public offering ... the Securities and Exchange Commission (the "SEC"). The offering ... can be no assurance as to whether or when ... actual size or terms of the offering. Cryoport also ...
Breaking Medicine Technology: